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Sepsis remains a serious problem in critically ill patients with
the mortality increasing to over half when there is attendant
acute kidney injury. a-Melanocyte-stimulating hormone is a
potent anti-inflammatory cytokine that inhibits many forms
of inflammation including that with acute kidney injury. We
tested whether a new a-melanocyte-stimulating hormone
analogue (AP214), which has increased binding affinity to
melanocortin receptors, improves sepsis-induced kidney
injury and mortality using a cecal ligation and puncture
mouse model. In the lethal cecal ligation-puncture model of
sepsis, severe hypotension and bradycardia resulted and
AP214 attenuated acute kidney injury of the lethal model
with a bell-shaped dose-response curve. An optimum AP214
dose reduced acute kidney injury even when it was
administered 6 h after surgery and it significantly improved
blood pressure and heart rate. AP214 reduced serum TNF-a
and IL-10 levels with a bell-shaped dose-response curve.
Additionally; NF-jB activation in the kidney and spleen, and
splenocyte apoptosis were decreased by the treatment.
AP214 significantly improved survival in both lethal and
sublethal models. We have shown that AP214 improves
hemodynamic failure, acute kidney injury, mortality and
splenocyte apoptosis attenuating pro- and anti-inflammatory
actions due to sepsis.
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Sepsis is one of the major causes of mortality, and the
incidence of sepsis in the United States is still increasing.1
Acute kidney injury (AKI) is also associated with a high
mortality rate,2 and AKI and sepsis increase mortality
synergistically; septic AKI patients show worse mortality
compared with non-septic AKI patients,3 whereas renal
dysfunction in septic patients increases mortality.4 However,
therapies to treat or prevent sepsis-induced AKI are largely
ineffective, and novel drugs available at clinical settings are
urgently required.
Several preclinical animal models have been developed to
evaluate the possible efficacy of drugs on sepsis-induced
AKI.5 Among them, the cecal ligation and puncture (CLP)
model is widely used because the resulting polymicrobial
sepsis mimics many features of human sepsis.6 We have
already demonstrated the efficacy of several drugs by a
clinically relevant sepsis-induced AKI model based on CLP.7–9
In this model, animals were treated with fluid resuscitation
and antibiotics similar to septic patients in an intensive care
unit. AKI can be detected within 6 h after surgery, by a
sensitive magnetic resonance imaging technique9 and within
12 h after CLP by measurement of serum creatinine.7
Moreover, our model shows not only kidney injury but also
multiple organ failure, such as liver damage and splenocyte
apoptosis.7,10 In this study, we further developed our CLP
model with some modifications in terms of mouse strain,
length of ligated cecum, and volume of fluid resuscitation.
a-Melanocyte-stimulating hormone (a-MSH) darkens
skin pigmentation in amphibians, rodents, and humans;
however, it is also a potent anti-inflammatory cytokine that
decreases inflammatory cytokines, nitric oxide production,
and expression of a neutrophil adhesion molecule.11,12
a-MSH inhibits multiple forms of inflammation and shows
protective effects on AKI induced by ischemia/reperfusion
and cisplatin injection.13–18 a-MSH also showed protective
effects in other experimental animal models such as brain
ischemic injury,19 mesenteric ischemia/reperfusion injury,20
endotoxin-induced hepatitis,21 cutaneous vasculitis,22 and
inflammatory bowel disease.23 Lipton et al.24 showed a
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protective effect of native a-MSH on survival of CLP animals,
although they did not measure sepsis-induced AKI or other
organ failure. The purpose of this study was to examine the
effect of the a-MSH analogue AP214, which has an additional
six lysine residues at the amino terminus, on sepsis-induced
AKI and mortality in a newly modified mouse sepsis model
of CLP.
RESULTS
Effects of AP214 treatment on AKI induced by lethal CLP in
young CD-1 mice
Lethal polymicrobial sepsis was induced in 8-week-old
outbred CD-1 mice by placing a ligature at 15 mm from
the tip of the cecum and puncturing it twice with a 21-G
needle. Serum creatinine increased 18 h after surgery
demonstrating the occurrence of AKI. Renal morphologic
evaluation performed 18 h after surgery showed mild tubular
damage with vacuolization but no thrombosis, tubular
necrosis, infiltrating inflammatory cells, or cast formation
both in the cortex and in the outer stripe of outer medulla
(OSOM) (Figure 1). These histological damages were similar
to our previous studies in aged C57BL/6 mice.7–10 Body
weight did not increase in CD-1 mice, in contrast to our
previous report that showed a 7% increase,7 because the
volume of fluid therapy that started at 6 h after surgery and
every 12 h thereafter was reduced from 1.5 to 1.0 ml (data not
shown).
Treatment with AP214 attenuated AKI with a bell-shaped
dose–response curve; 10 mg treatment had a maximum effect,
1 mg showed a partial improvement, whereas neither 0.1 nor
50 mg treatment showed any effect against AKI (Figure 2a).
Native a-MSH treatment with 6.8 mg (an amount equimolar
to 10 mg AP214) also showed a protective effect on AKI
(Figure 2b). AP214 treatment at the dose of 10 mg
significantly ameliorated tubular damage in both the cortex
and the OSOM (Figures 1 and 3a, b). Treatment with the
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Figure 1 | Renal pathology. Animals were killed 18 h after lethal CLP
surgery. Representative renal histology of the cortex and the
OSOM in each group was shown. Original magnification  400.
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Figure 2 | Effect of AP214 on AKI induced by CLP. Mice were
killed 18 h after lethal CLP surgery for measurement of serum
creatinine by HPLC method. AP214 was injected (a, b) at 0 and 6 h
or (c) only at 6 h (delayed treatment). (b) Equimolar native a-MSH
(6.8mg) was injected at 0 and 6 h. Values are mean±s.e.m.
(n¼ 4–5 in sham-operated group, n¼ 10–14 in CLP group,
n¼ 7–10 in each AP214 treatment group). #Po0.05 vs CLP. HPLC,
high-performance liquid chromatography.
Kidney International (2008) 73, 1266–1274 1267
K Doi et al.: Effect of a-MSH analogue on sepsis-induced AKI o r i g i n a l a r t i c l e
maximally efficacious dose of 10 mg reduced AKI and
histological damage even when started 6 h after surgery
(Figures 2c and 3c, d and Figure S1). Treatment of sham-
operated mice with 10 mg of AP214 did not cause any change
in serum creatinine (data not shown).
Severe neutropenia was improved by AP214
The present lethal CLP model showed severe neutropenia at
18 h after surgery in accordance with previous reports.25,26
AP214 treatment at the dose of 10 mg significantly improved
neutropenia in peripheral blood in lethal CLP, although there
was no significant difference in the total white blood
cell count between the CLP and AP214 treatment groups.
AP214 did not cause any change in sham-operated mice
(Table 1).
Effects of AP214 treatment on liver damage in lethal CLP
We previously reported liver damage in the mouse CLP
model.10 The lethal CLP model showed significant increases
of aspartate aminotransferase and alanine aminotransferase
at 18 h after surgery compared with sham-operated animals
(aspartate aminotransferase: vehicle 680.9±92.5 U l1
(n¼ 14), sham 126.4±22.3 U l1 (n¼ 5), Po0.05; alanine
aminotransferase: vehicle 314.3±30.1 U l1 (n¼ 14), sham
40.6±3.8 U l1 (n¼ 5), Po0.05). AP214 treatment at the
dose of 10 mg significantly attenuated liver damage in
lethal CLP (Figure 4a and b) and did not cause any change
in sham-operated mice (data not shown). Delayed 10 mg
AP214 treatment that was started at 6 h after surgery also
showed a protective effect against liver damage by lethal CLP
(Figure 4c and d).
AP214 treatment improved hypotension in lethal CLP
Blood pressure and heart rate measurement was performed in
conscious animals by radiotelemetry. Injection of AP214 on
normal CD-1 mice at the dose of 10 mg did not alter blood
pressure and heart rate compared with vehicle injection
(Figure 5a and b). Sepsis induced by lethal CLP surgery
caused severe hypotension and decrease of heart rate. AP214
treatment prevented the progression of severe hypotension
and bradycardia (blood pressure at 18 h: sham 112.4±
2.8 mm Hg (n¼ 3), CLPþ vehicle 54.4±4.7 mm Hg (n¼ 5),
CLPþAP214 75.7±6.4 mm Hg (n¼ 5), Po0.05 (vs CLPþ
vehicle); heart rate: sham 459.4±77.0 beats per min (b.p.m.)
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Figure 3 | Pathological score. AP214 was injected (a, b) at 0 and
6 h or (c, d) only at 6 h (delayed treatment). The tubular damage
score (see the Materials and Methods section) was measured in
the cortex (a, c) and the OSOM (b, d). Values are mean±s.e.m.
(n¼ 4 in sham-operated group, n¼ 8 in CLP group, n¼ 6 in each
AP214 group). #Po0.05 vs CLP.
Table 1 | Effect of AP214 on blood leukocytes
WBC (ll1) Neutrophil (ll1)
Lymphocyte+
monocyte (ll1)
Sham+NS (n=4) 5673±130 1247±92 4318±163
Sham+AP214 (n=4) 5125±550 1307±130 3758±429
CLP+NS (n=7) 1520±335 88±69 1413±353
CLP+AP214 (n=7) 1049±247 679±131# 347±116#
NS, normal saline; WBC, white blood cell.
#Po0.05 vs CLP+NS.
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Figure 4 | Effect of AP214 on liver damage induced by CLP.
Serum AST and ALT were measured 18 h after lethal CLP surgery.
AP214 was injected (a, b) at 0 and 6 h or (c, d) only at 6 h (delayed
treatment). Values are mean±s.e.m. (n¼ 5 in sham-operated
group, n¼ 14 in CLP group, n¼ 7 in AP214 group). #Po0.05 vs
CLP. ALT, alanine aminotransferase; AST, aspartate
aminotransferase.
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(n¼ 3), CLPþ vehicle 197.6±14.2 b.p.m. (n¼ 5), CLPþ
AP214 459.4±77.0 b.p.m. (n¼ 5), Po0.05 (vs CLPþ
vehicle)) (Figure 5c and d).
Serum tumor necrosis factor-a and interleukin-10 levels in
lethal CLP were suppressed by AP214
We evaluated serum tumor necrosis factor-a (TNF-a) and
interleukin-10 (IL-10) levels by enzyme-linked immunosor-
bent assay 18 h after surgery in lethal CLP animals. Both
serum TNF-a and IL-10 levels increased in CLP animals
(TNF-a: vehicle 572.5±65.5 pg ml1 (n¼ 14), sham
55.3±5.3 pg ml1 (n¼ 5), Po0.05; IL-10: vehicle
1365.2±182.4 pg ml1 (n¼ 14), sham 20.2±9.3 pg ml1
(n¼ 5), Po0.05). Administration of AP214 reduced serum
TNF-a and IL-10 levels with bell-shaped dose–response
curves (Figure 6a and b). AP214 had a maximum effect on
sepsis-induced AKI at the dose of 10 mg and the same dose of
10 mg also had a maximum effect on reducing serum TNF-a
and IL-10. Delayed AP214 treatment (10 mg) also reduced
serum TNF-a and IL-10 (Figure 6c and d).
Nuclear factor-jB activation in the kidney and spleen was
inhibited by AP214
We examined nuclear factor-kB (NF-kB) activation in the
kidney and spleen because a-MSH has been reported to
inhibit NF-kB activation induced by several inflammatory
signals.27 NF-kB activation in the kidney and spleen at 18 h
after lethal CLP surgery was significantly increased compared
with sham-operated animals. AP214 treatment at the dose of
10 mg significantly inhibited the increase of NF-kB activation
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Figure 5 | AP214 prevented hypotension and bradycardia
induced by CLP. (a, b) Telemetric recordings of MAP and HR after
injection of AP214 (closed circle) or vehicle (open circle) to normal
CD-1 mice are shown. Values are mean±s.e.m. (n¼ 5 in vehicle
group, n¼ 5 in AP214 group). (c, d) MAP and HR in CLP mice with
AP214 treatment (closed circle) or vehicle injection (open circle),
and sham-operated group (open square) are shown. Values are
mean±s.e.m. (n¼ 3 in sham-operated group, n¼ 5 in CLP
group, n¼ 5 in AP214 group). HR, heart rate; MAP, mean arterial
pressure.
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Figure 6 | AP214 reduced serum TNF-a and IL-10. Serum TNF-a
and IL-10 levels were measured by enzyme-linked
immunosorbent assay. AP214 was injected at (a, b) 0 and 6 h or
(c, d) only at 6 h (delayed treatment). Animals were killed 18 h
after lethal CLP surgery. Values are mean±s.e.m. (n¼ 5 in sham-
operated group, n¼ 14 in CLP group, n¼ 7 in each AP214 group).
#Po0.05 vs CLP.
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both in the kidney and in the spleen (Figure 7a and b).
Delayed AP214 treatment (10 mg) also decreased NF-kB
activation (Figure 7c and d).
AP214 reduced splenocyte apoptosis in lethal CLP
Lymphocyte apoptosis is reported to contribute to sepsis
severity.28 Therefore, we investigated the effect of AP214 on
splenocyte apoptosis. Splenocyte apoptosis was evaluated by
immunohistochemical analysis of activated caspase-3. In
sham-operated animals, activated caspase-3-positive stained
cells were rarely found in the spleen (Figure 8a). CLP
increased activated caspase-3-positive stained cells pro-
foundly in the white pulp of the spleen at 18 h after surgery,
and AP214 treatment at the dose of 10 mg significantly
reduced splenocyte apoptosis (Figure 8c and d). Delayed
AP214 treatment (10 mg) also reduced splenocyte apoptosis
(Figure 8e). No apoptotic cell was detectable in the kidney, as
previously reported.10
AP214 improved survival in both lethal and sublethal CLP
We evaluated the effects of 10 mg AP214 treatment on survival
after lethal CLP, in which 15 mm of the cecum was ligated.
Drug or vehicle was administered just after surgery, at 6 h
post-surgery, and every 12 h thereafter. All vehicle-treated
animals in the lethal CLP model died within 48 h after
surgery; treatment with AP214 improved survival (Figure 9).
We also evaluated the effect of AP214 on the sublethal CLP
model, in which only 8 mm of the cecum was ligated. After
sublethal CLP, 30–40% of control animals survived at 96 h
and treatment with AP214 increased the survival rate to 65%
(Figure 4). After sublethal CLP, AKI was evaluated at 18 h
after surgery. Compared with our lethal CLP model, the
control animals in sublethal CLP showed lower serum
creatinine levels, and treatment with AP214 at the dose of
10 mg showed a trend toward decreased serum creatinine
(vehicle 0.29±0.06 mg per 100 ml (n¼ 15) vs AP214
0.19±0.04 mg per 100 ml (n¼ 15), P¼ 0.089).
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Figure 7 | NF-jB activation in the kidney and spleen. NF-kB
activation in the kidney and spleen was evaluated by enzyme-
linked immunosorbent assay. AP214 was injected at (a, b) 0 and
6 h or (c, d) only at 6 h (delayed treatment). OD value of each
sample was normalized with that of Raji cell nuclear extract.
Values are mean±s.e.m. (n¼ 4 in sham-operated group, n¼ 6–7
in CLP group, n¼ 6–7 in AP214 group). #Po0.05 vs CLP.
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Figure 8 | Immunohistochemical analysis of activated caspase-3 in the spleen. Immunohistochemistry with anti-activated caspase-3
antibody in (a) sham-operated group, (b) CLP group, (c) AP214-treated group; original magnification  400. Counts of positive stained
cells were shown. AP214 was injected (d) at 0 and 6 h or (e) only at 6 h (delayed treatment). Values are mean±s.e.m. (n¼ 3 in sham-
operated group, n¼ 5 in CLP group, n¼ 5 in AP214 group). #Po0.05 vs CLP.
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DISCUSSION
We have evaluated the effects of the a-MSH analogue AP214
on sepsis-induced AKI and mortality by using a modified
rodent CLP sepsis model in outbred mice. AP214 showed a
protective effect on sepsis-induced AKI and improved
survival in lethal and sublethal CLP models. We also
demonstrated potential mechanisms of action of AP214 on
several pro- and anti-inflammatory pathways and splenocyte
apoptosis.
We developed a new CLP model as follows: we changed
the mouse strain from inbred C57BL/6 to outbred CD-1
mice, which are more representative of a genetically
heterogeneous human population. In our previous reports,
we used aged C57BL/6 mice because CLP surgery in young
C57BL/6 mice produced a wide range of creatinine values
without much histologic evidence of renal damage.7 In
contrast, 8-week-old CD-1 mice showed more pathological
renal damage compared with young C57BL/6 mice. As the
length of the ligated cecum determines the severity in other
CLP models,29,30 we developed two different models: a lethal
CLP model (ligation at 15 mm from the end of the cecum)
and a sublethal CLP model (8 mm) (Figure 9). Finally, we
reduced the volume of fluid resuscitation compared to our
previous studies to avoid volume overload and to maintain
constant body weight.
Mice subjected to lethal CLP were severely hypotensive
and bradycardic (Figure 5). The radiotelemetry data in this
study indicate that systemic circulation failure induced by
CLP may contribute to organ hypoperfusion, including
hypoperfusion of the kidney that has been shown previously
in CLP animals.8,31 Severe systemic circulation failure might
contribute to sepsis-induced AKI in this model. AP214
significantly improved blood pressure and heart rate. Recent
studies revealed that MSHs, including a-MSH, have im-
portant roles in cardiovascular regulation.32 It has been
reported that a-MSH increases blood pressure and heart rate
by activation of melanocortin receptor (MCR)4, which is
primarily expressed in the central nervous system.33 Hence,
AP214 might improve sepsis via a direct hemodynamic effect.
However, exogenous a-MSH increases blood pressure only
when it is administered by intracerebroventricular injection;
intravenous injection does not alter blood pressure in
rodents.33,34 Similarly, intravenous AP214 did not increase
blood pressure and heart rate in normal mice. However, these
data do not clarify the precise mechanism by which
intravenously injected AP214 exerts its hemodynamic effects
on septic CLP mice, as it is not possible to differentiate a
direct hemodynamic effect from an initial anti-inflammatory
effect with subsequent improvement in hemodynamics.
a-MSH has broad anti-inflammatory properties and
inhibits organ injury in various inflammatory animal
models.35 We have already demonstrated that the native
a-MSH ameliorated AKI caused by ischemia/reperfusion
injury.13–15,17,18 Although one report showed that native
a-MSH improved survival in experimental sepsis induced by
CLP, its effect on sepsis-induced AKI and multiple organ
failure was not determined.24 In this study, we found that the
a-MSH analogue AP214 improved sepsis-induced multiple
organ failure, including AKI and mortality. Moreover, we
found that AP214 had a bell-shaped dose–response curve for
sepsis-induced AKI. There are several reports that demon-
strated biphasic dose–response curves in the anti-inflamma-
tory influence of a-MSH. Both the large and small doses were
ineffective for in vivo animal models of ear swelling induced
by picryl chloride36,37 and crystal-induced peritonitis,38 and
for in vitro cell culture models such as TNF-a production in
microglia,39 cyclic AMP production in mast cells,40 and
glutathione peroxidase activity in melanocytes and keratino-
cytes.41 The cause of this phenomenon is unknown but might
be explained in part by receptor downregulation to avoid
excess effects. Equimolar native a-MSH also showed a
protective effect on sepsis-induced AKI, although binding
affinity of AP214 for MCRs in vitro was higher than that of
native a-MSH. These data suggest that the effects of AP214
in vivo may not be straightforward and confounded by
pharmacokinetic parameters and/or indirect regulatory
influences. Further evaluations would be required to clarify
the mechanisms of these biphasic responses of AP214 in both
physiological and pathological in vivo conditions.
Failure to regulate hyperactivation of the inflammatory
system plays an important role in the pathophysiology of
sepsis, and blocking inflammatory mediators has been often
proposed as a treatment strategy for sepsis. However, many
clinical trials with drugs that inhibit specific inflammatory
mediators have not been successful. a-MSH has a breadth of
anti-inflammatory activities and can improve inflammatory
disorders through suppressing multiple pathways. Moreover,
a-MSH modulates inflammatory responses through inhibi-
tion of the nuclear transcription factor NF-kB activation,
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which plays the central role in immune and inflammation
systems.27 In this study, we demonstrated the inhibition of
systemic TNF-a production (Figure 6) and renal and splenic
NF-kB activation (Figure 7). AP214 reduced serum TNF-a
levels with a bell-shaped dose–response curve similar to its
effects on serum creatinine levels. This indicates that
modulation of the exacerbated inflammatory response is
beneficial for AKI induced by lethal CLP. AP214 can be an
agonist of several MCRs (MCR1, MCR3, MCR4, and MCR5).
MCR1 and MCR3 are known to mediate anti-inflammatory
effects, and MCR4 regulates hemodynamics in the central
nerve system, as described above, whereas MCR5 has been
implicated in multiple exocrine functions.42 Further investi-
gation on the contribution of each MCR pathway will be
necessary to further understand the mechanisms of action of
a-MSH in sepsis and to minimize unwanted effects from
other MCRs.
The action of a-MSH is reminiscent of corticosteroids
because both of them have multiple anti-inflammatory effects
through several mechanisms, including inhibiting the NF-kB
pathway.43 It has been recently suggested that ‘physiologic’
but not high doses of corticosteroids might be beneficial to
septic patients.44 Our data indicate that AP214 similarly has a
relatively narrow therapeutic window, as 10 mg treatment but
not 50 mg showed protective effects in CLP animals. There-
fore, translation of AP214 to studies in human sepsis will
likely require precise evaluation of the pharmacokinetics and
dose responses of AP214 in humans before large-scale clinical
trials can be initiated.
Serum IL-10 levels were increased in our mouse sepsis
model and suppressed after AP214 treatment. Although the
role of IL-10 as an anti-inflammatory cytokine is apparent in
renal ischemia/reperfusion and cisplatin-induced renal in-
jury,16 the role of IL-10 and its relationship to a-MSH in
sepsis is less clear. IL-10-knockout mice showed higher
mortality in CLP than wild-type mice, and anti-IL-10
monoclonal antibody treatment worsened the survival after
CLP when injected at 0 or 2 h before surgery.45,46 On the
other hand, anti-IL-10 monoclonal antibody treatment was
protective when it was injected 10 h after CLP.46 Therefore,
IL-10 appears to have dual effects on sepsis that depends on
the timing. The finding that AP214 decreased serum IL-10
levels at 18 h after surgery in this study indicates that
excessive IL-10 at the late phase might worsen sepsis-induced
AKI.
The relationship between a-MSH and IL-10 is also
unclear. In vitro, a-MSH modestly stimulates IL-10 produc-
tion in human peripheral blood mononuclear cells.47,48 There
is one report in vivo showing no effect of [Nle4, D-Phe7]-
a-MSH on lipopolysaccharide-stimulated plasma IL-10 levels
in monkeys.49 Our results clearly showed that the increase of
serum IL-10 by CLP was attenuated by a-MSH. One possible
explanation for this discrepancy is that lipopolysaccharide,
especially at the subclinical dose used in the primate study,49
causes an increase in IL-10 that is more resistant to a-MSH.
The observation that lipopolysaccharide signaling via
Toll-like receptor 4 does not contribute to AKI in
polymicrobial sepsis by CLP supports this view.10 The
mechanisms of a-MSH to decrease IL-10 production in vivo
during sepsis need further investigation. Because the effect of
IL-10 disruption on sepsis outcomes depends on timing, the
success of AP214 as a clinical therapeutic may require
optimization of the timing of administration.
Apoptosis was detected predominantly in lymphocytes in
human sepsis,50 and several strategies to decrease immune
cell apoptosis have been reported to improve the survival rate
of CLP animals.51–53 CLP animals in this study showed
splenocyte apoptosis, which was reduced after AP214
treatment. a-MSH has been reported to activate antiapop-
totic pathways in cultured melanocytes54,55 and reduce renal
tubular cell apoptosis in a bilateral ureteral obstruction
model.56 It might be possible that AP214 acts on splenocytes
and suppresses apoptotic pathways.
Conclusion
The a-MSH analogue AP214 ameliorated severe septic shock
and sepsis-induced AKI and mortality in outbred CD-1
mouse models of polymicrobial sepsis. We found the biphasic
dose–response curves of AP214 against AKI and cytokine
productions, indicating that strict regulation of a-MSH
dosing might be important in sepsis. We also demonstrated
that AP214 improved systemic hemodynamics, pro- and
anti-inflammatory actions, renal and splenic NF-kB activa-
tion, and splenocyte apoptosis. These results suggested that
AP214 might be useful for the prevention or treatment of
sepsis in humans.
MATERIALS AND METHODS
Reagents
AP214 is an analogue of a-MSH modified with six lysine residues
at the N terminus of native a-MSH (Ac-KKKKKKSYS
MEHFRWGKPV-NH2). AP214 was provided by Action Pharma
A/S (Aarhus and Copenhagen, Denmark). AP214 has a higher binding
affinity for MCRs than the native a-MSH (inhibition constants
(AP214 vs MSH): MCR1: 2.9 vs 5.7 nM; MCR3: 1.9 vs 22 nM; MCR4:
3.7 vs 24 nM; and MCR5: 110 vs 1300 nM (Jonassen et al. J Am Soc
Nephrol 2006; S17: S326A)). Native a-MSH was purchased from
Phoenix Pharmaceuticals (Mountain View, CA, USA).
CLP model
All animal experiments were conducted in accordance with an
animal study protocol approved by NIDDK Animal Care and Use
Committee. Eight-week-old male CD-1 mice (Charles River
Laboratories, Wilmington, MA, USA) were allowed food and water
ad libitum. CLP was performed as previously described with some
modifications.7 Under isoflurane anesthesia, a 1.5-cm midline
incision was made and the cecum was exposed. A 4-0 silk ligature
was placed 15 mm from the cecal tip in lethal CLP and 8 mm in
sublethal CLP. The cecum was punctured twice with a 21-G needle
and gently squeezed to confirm leakage of cecal contents. In sham-
operated animals, the cecum was located, but neither ligated nor
punctured. The abdominal incision was closed in two layers with 4-0
silk sutures, and 1 ml of prewarmed normal saline (NS) was injected
intraperitoneally. Treatment with fluid and antibiotic was started at
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6 h after surgery with subcutaneous injection of imipenem/cilastatin
(14 mg kg1) in 1 ml of NS, and treatment in the survival study was
continued every 12 h with imipenem/cilastatin (7 mg kg1) in 1 ml
of NS. AP214 (0.1, 1, 10, and 50mg) or native a-MSH (6.8 mg)
dissolved in 0.15 ml of NS was administered intravenously as a
bolus just after surgery, at 6 h post-surgery, and then every 12 h
thereafter in the survival study. In the vehicle-treated CLP
group, animals received 0.15 ml of NS intravenously at the indicated
times. In another experiment, 10 mg of AP214 dissolved in 0.15 ml of
NS or only vehicle was given intravenously 6 h after surgery
(delayed-treatment group). Blood, kidneys, and spleen were
collected under isoflurane anesthesia at 18 h after surgery except
for survival study.
Morphologic evaluation of kidneys
Kidney specimens fixed in 10% formalin and embedded in paraffin
were stained with periodic acid-Schiff reagent. Histologic changes in
the cortex and in the OSOM were scored by a blinded observer.7
Measurement of blood chemistry, blood cell counts, and
cytokines
Serum creatinine was measured by high-performance liquid
chromatography.57 Aspartate aminotransferase and alanine amino-
transferase were measured by autoanalyzer (Hitachi 917; Boehringer
Mannheim, Indianapolis, IN, USA). Peripheral blood cell counts
were analyzed by an automated hematology analyzer (Abott Cell-
Dyn 3500; GMI, Ramsey, MN, USA). TNF-a and IL-10 were
measured by enzyme-linked immunosorbent assay (R&D Systems,
Minneapolis, MN, USA).
Measurement of blood pressure and heart rate
The mean blood pressure and heart rate were measured by
radiotelemetry. Under anesthesia with ketamine (50 mg kg1),
xylazine (5 mg kg1), and acepromazine (1 mg kg1), a telemeter
catheter was implanted in the left carotid artery and advanced to
reach the aortic arch. The attached telemetry transmitter (model
TA11PA-C10; Data Sciences International, St Paul, MN, USA) was
placed in a subcutaneous pocket on the left flank 1 week before CLP
surgery or AP214 administration. The telemeter signals were
processed as previously described.58 Blood pressure and heart rate
data were analyzed from 6 h before CLP surgery for 24 h, or 20 min
before injection of AP214 or vehicle until 90 min after.
NF-jB activation assay
NF-kB p65 activity was quantified by using the TransAM Assay
(Active Motif, Carlsbad, CA, USA). Briefly, a NF-kB consensus
oligonucleotide bound to a 96-well plate was incubated with 100mg
whole-cell extracts from the kidney and the spleen, followed by p65
primary antibody and secondary antibody conjugated with horse-
radish peroxidase. The optical density (OD) values of peroxidase
reaction product from each sample were normalized with the OD
values of Raji nuclear extract (Active Motif).
Immunohistochemical analysis of activated caspase-3 in the
spleen
Immunohistochemical staining of 4 mm paraffin sections was
performed with anti-activated caspase-3 antibody (Cell Signaling
Technology, Beverly, MA, USA). The sections were deparaffinized,
incubated in 10 mmol l1 citrate buffer, pH 6.0, for 10 min at 95 1C,
and preincubated with 3% hydrogen peroxide for 10 min. After
blocking with goat serum, sections were incubated for 1 h at room
temperature with primary antibodies. Two-step immunohistochem-
ical staining with horseradish peroxidase-conjugated secondary
antibody was conducted (EnVisonþ System-HRP (diaminobenzi-
dine); DakoCytomation, Glostrup, Denmark) with diaminobenzi-
dine substrate, and then counterstained with hematoxylin. Positive
stained cells were counted from five randomly selected non-
overlapping  200 fields.
Statistical analysis
Results of statistical analyses are expressed as means±s.e.m.
Differences among experimental groups were confirmed by one-
way analysis of variance followed by Dunnett’s test for individual
comparison of group means vs the control group. Survival analyses
were compared by a log-rank test. These calculations were
performed with SigmaStat v3.10 (Systat Software Inc., Richmond,
CA, USA). The null hypothesis was rejected when Po0.05.
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